1 / 1

Revolutionizing Health: Impomed's Leading Cancer and Neurology Treatments

Experience a health revolution with Impomed's avant-garde cancer and neurology treatments. Our commitment to excellence merges breakthrough therapies with compassionate care, offering a transformative journey to recovery. Trust Impomed for cutting-edge solutions that redefine what's possible in healthcare. Your path to a healthier future starts here.

impo
Download Presentation

Revolutionizing Health: Impomed's Leading Cancer and Neurology Treatments

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FAM-TRASTUZUMAB DERUXTECAN Home | Cancer | Solid Tumors | FAM-TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN Injection Description Composition Dosage Indications "ENHERTU (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate. Fam-trastuzumab deruxtecan-nxki is an antibody- drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase inhibitor, via 3) a tetrapeptide-based cleavable linker.Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative.... ENHERTU (fam-trastuzumab deruxtecan-nxki) is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 100 mg of fam-trastuzumab deruxtecan-nxki, L-histidine (4.45 mg), L-histidine hydrochloride monohydrate (20.2 mg), polysorbate 80 (1.5 mg), and sucrose (450 mg). Following reconstitution with 5 mL of Sterile Water for Injection, USP, the resulting concentration of fam-trastuzumab deruxtecan-nxki is 20 mg/mL with a pH of 5.5. The resulting solution is administered by intravenous infusion following dilution. " Copyright © 2024 ImpoMed Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com

More Related